KHIRON LIFE SCIENCES CORP - KHRNF STOCK NEWS

Khiron Life Sciences Corp. launched new THC-dominant medical cannabis products in Europe, introducing the KHIRIOX 25/1 extract and non-irradiated flower varieties KHIRON Gelato 19/1 and KHIRON Caramel 5/7. These products, available via Pharmadrug Production GmbH, aim to meet high demand in Germany and the UK. The expansion enhances Khiron's portfolio, aligning with European market needs and potentially increasing profit margins. President Franziska Katterbach emphasized the strategic control over the value chain in Europe. The products cater to both healthcare providers and patients.

Khiron Life Sciences Corp. reported $9.1 million in revenues for H1 2022, marking a 62% year-over-year increase. The company's Q2 2022 net loss decreased 60% quarter-over-quarter to ($2.2 million), with an Adjusted EBITDA loss of ($2.3 million), down 30% from Q1 2022. Gross margin for medical cannabis surged to 76%.

Key developments included the acquisition of Pharmadrug GmbH, enhancing its European presence, and the opening of a new Zerenia clinic in Rio de Janeiro, solidifying its market strategy.

Khiron Life Sciences Corp. (TSXV: KHRN)(OTCQX: KHRNF) announced a Conference Call scheduled for August 29, 2022, at 10:00 a.m. ET to discuss its second-quarter results for the period ending June 30, 2022. The Company will release its financial results prior to the call, which will feature a 45-minute presentation followed by a Q&A session. Interested investors and analysts can register for the event online. Khiron is recognized as a leader in medical cannabis in Latin America and Europe.

Khiron Life Sciences Corp. has announced the opening of Brazil's first Zerenia™ clinic in Ipanema, Rio de Janeiro, which will provide around 23,000 patient consultations annually. This expansion into Brazil targets a market of over 210 million people, leveraging Khiron's successful patient acquisition model. The clinic will house more than 13 doctors and offers services like telehealth and in-person consultations for various medical conditions. CEO Alvaro Torres emphasized the potential for replicating Khiron's global success in this lucrative market.

Khiron Life Sciences Corp. has successfully acquired Pharmadrug Production GmbH, enhancing its presence in Europe with EU-GMP certified manufacturing. This acquisition provides direct access to German pharmacies, allowing Khiron to increase gross margins and expand its product portfolio, which includes exclusive flower varieties and full-spectrum extracts. Khiron issued approximately 5.97 million common shares and a promissory note totaling $974,137 to Pharmadrug. This strategic move aligns with Khiron's asset-light strategy and aims to expedite sales and product availability in the German market.

Khiron Life Sciences Corp. announced the appointment of Helen Bellwood as Interim CFO, effective immediately, replacing Swapan Kakumanu of RTB LLP. Bellwood, who has over 24 years of finance experience, previously served as Head of Finance for Khiron's European operations. Under her leadership, the company reported over 1 million CAD in revenue in Q1 2022, with a focus on achieving short-term EBITDA positivity. CEO Alvaro Torres expressed confidence in Bellwood’s ability to lead financial operations in Europe and Latin America.

Khiron Life Sciences Corp. is expanding its presence into Spain, following its success in Latin America. With a Spanish subsidiary established in 2019, the company aims to introduce cannabinoid therapies to an estimated 700,000 potential patients in Spain. Khiron's collaboration with the Spanish Agency of Medicines and ongoing educational initiatives position it well for this regulatory shift. The acquisition of a EU GMP-certified pharmaceuticals manufacturer in Germany will enhance Khiron's growth and market presence, enabling direct access to European pharmacies.

Khiron Life Sciences Corp. has achieved a record number of patients treated with its products, surpassing 100,000 bottles sold. The company reported Q1 2022 revenue of $4.6 million, reflecting a 65% increase year-over-year and $2.6 million in medical cannabis revenue, a 470% increase. Khiron's expansion in Europe and Latin America, including significant operations in Colombia and Germany, positions it as a leader in the medical cannabis market. The company has also acquired Pharmadrug GmbH to enhance its manufacturing capabilities.

Khiron Life Sciences Corp. announced the results of its 2022 Annual General and Special Meeting held on June 23, 2022, where shareholders approved all proposed resolutions. Key decisions included the re-appointment of BDO Canada LLP as auditors, fixing the board size to six members, and electing all management nominees to the board. The meeting saw the representation of 44,108,709 common shares, accounting for 23.751% of the total. Following the meeting, Deborah Rosati resigned from the board. Khiron operates in the medical cannabis sector across Latin America and Europe.